Home
About
FAQ
History (3)
A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
Angiotensin-(1-7) reduces lung tumor incidence in a novel bitransgenic Ki-rasG12C mouse model of lung tumorigenesis through a reduction in cyclooxygenase-2
Predicting outcome on admission and post-admission for acetaminophen-induced acute liver failure using classification and regression tree models.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
Biography
contributor
Principal Investigator
Time
start date
2019-09-01
end date
2023-08-31
